MoonLake Immunotherapeutics (MLTX) Tops Q3 EPS by 5c

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q3 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Movano (MOVE) Misses Q2 EPS by 195c